CO6390043A2 - Formulaciones que comprenden ceftiofur y cetoprofeno o ceftiofur y alcohol bencílico - Google Patents
Formulaciones que comprenden ceftiofur y cetoprofeno o ceftiofur y alcohol bencílicoInfo
- Publication number
- CO6390043A2 CO6390043A2 CO11069892A CO11069892A CO6390043A2 CO 6390043 A2 CO6390043 A2 CO 6390043A2 CO 11069892 A CO11069892 A CO 11069892A CO 11069892 A CO11069892 A CO 11069892A CO 6390043 A2 CO6390043 A2 CO 6390043A2
- Authority
- CO
- Colombia
- Prior art keywords
- ceftiofur
- formulations
- alcohol
- cetoprofen
- bencyl
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- ZBHXIWJRIFEVQY-IHMPYVIRSA-N ceftiofur Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 ZBHXIWJRIFEVQY-IHMPYVIRSA-N 0.000 title abstract 3
- 229960005229 ceftiofur Drugs 0.000 title abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 3
- 241000283690 Bos taurus Species 0.000 abstract 2
- 208000023504 respiratory system disease Diseases 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 235000019445 benzyl alcohol Nutrition 0.000 abstract 1
- 229960004217 benzyl alcohol Drugs 0.000 abstract 1
- 239000002270 dispersing agent Substances 0.000 abstract 1
- 239000008394 flocculating agent Substances 0.000 abstract 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 abstract 1
- 229960000991 ketoprofen Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000009736 wetting Methods 0.000 abstract 1
- 239000000080 wetting agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se relaciona a formulaciones veterinarias o farmacéuticas que pueden comprender ceftiofur, cetoprofeno, alcohol bencílico o combinaciones efectivas de los mismos. Las formulaciones de la presente invención pueden incluir un agente humectante o dispersante, un conservador, un agente floculante o mejorador de capacidad de resuspensión y/o un vehículo de aceite biocompatible. Esta invención también proporciona, inter alia, formulaciones para el tratamiento, control y prevención de desórdenes respiratorios, particularmente enfermedad respiratoria bovina (BRD) en animales de sangre caliente, tal como ganado. Esta invención además proporciona métodos para incrementar la capacidad de resuspensión de una formulación aceitosa que puede comprender la adición.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11603108P | 2008-11-19 | 2008-11-19 | |
US11976408P | 2008-12-04 | 2008-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6390043A2 true CO6390043A2 (es) | 2012-02-29 |
Family
ID=41682851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO11069892A CO6390043A2 (es) | 2008-11-19 | 2011-06-07 | Formulaciones que comprenden ceftiofur y cetoprofeno o ceftiofur y alcohol bencílico |
Country Status (15)
Country | Link |
---|---|
US (1) | US20100125060A1 (es) |
EP (1) | EP2367572B1 (es) |
JP (1) | JP5685193B2 (es) |
KR (1) | KR101748890B1 (es) |
CN (1) | CN102341125B (es) |
AU (1) | AU2009316708B2 (es) |
BR (1) | BRPI0922041A8 (es) |
CA (1) | CA2743551C (es) |
CL (1) | CL2011001177A1 (es) |
CO (1) | CO6390043A2 (es) |
ES (1) | ES2693700T3 (es) |
MX (1) | MX2011005217A (es) |
NZ (1) | NZ592984A (es) |
WO (1) | WO2010059717A2 (es) |
ZA (1) | ZA201103479B (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2477590A (en) * | 2010-02-05 | 2011-08-10 | Biocopea Ltd | A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier |
US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US9737500B2 (en) | 2010-10-29 | 2017-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US8895537B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating cardiovascular diseases |
US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
GB201018289D0 (en) * | 2010-10-29 | 2010-12-15 | Biocopea Ltd | Treatment of respiratory disorders |
US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
AR090775A1 (es) * | 2012-04-23 | 2014-12-03 | Otsuka Pharma Co Ltd | Preparado inyectable |
ES2682761T3 (es) | 2012-05-18 | 2018-09-21 | Genentech, Inc. | Formulaciones de anticuerpos monoclonales de alta concentración |
UY34913A (es) * | 2012-07-17 | 2013-12-31 | Bayer New Zealand Ltd | Formaciones inyectables de antibiótico y sus métodos de aplicación |
FR3000392B1 (fr) | 2012-12-27 | 2015-03-27 | Virbac | Nouvelles compositions pharmaceutiques veterinaires et leur procede de preparation |
KR101586789B1 (ko) * | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
KR101586791B1 (ko) | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | GnRH 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
DK3082762T3 (da) * | 2013-12-16 | 2021-12-06 | Zoetis Services Llc | Langtidsvirkende ketoprofensammensætninger |
WO2017119928A1 (en) * | 2016-01-08 | 2017-07-13 | Abon Pharmaceuticals, Llc | Long acting injectable formulations |
CN107049943B (zh) * | 2017-05-10 | 2020-02-14 | 郑州百瑞动物药业有限公司 | 奶牛用盐酸头孢噻呋注射液及其制备方法 |
JP7323630B2 (ja) * | 2019-03-06 | 2023-08-08 | ゾエティス・サービシーズ・エルエルシー | 使用準備が整った注射用製剤 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1181672B (it) * | 1984-10-25 | 1987-09-30 | Upjohn Co | Cefalosporina alogenidrato cristallino |
DE3887691T2 (de) * | 1987-11-10 | 1994-06-09 | Upjohn Co | Cephalosporin-antibiotika. |
ATE202109T1 (de) * | 1993-03-12 | 2001-06-15 | Upjohn Co | Kristallines ceftiofur (freie säure) |
US5736151A (en) * | 1996-12-09 | 1998-04-07 | Pharmacia & Upjohn Company | Antibiotic oil suspensions |
US6074657A (en) * | 1997-03-20 | 2000-06-13 | Pharmacia & Upjohn Company | Administration of an injectable antibiotic in the ear of an animal |
JP2004504357A (ja) * | 2000-07-26 | 2004-02-12 | アルコン,インコーポレイテッド | ポリマー性懸濁化剤を含有しない薬学的懸濁組成物 |
AU2001288322A1 (en) * | 2000-09-12 | 2002-03-26 | Pharmacia And Upjohn Company Llc | Pharmaceutical composition having specific water activity |
CA2416566C (en) * | 2000-09-12 | 2011-05-31 | Pharmacia & Upjohn Company | Depot formulation comprising ceftiofur and peroxidized natural oil |
KR100423895B1 (ko) * | 2001-02-19 | 2004-03-24 | 주식회사 엘지생명과학 | 셉티오퍼 하이드로클로라이드의 현탁제 조성물 |
US20040022815A1 (en) * | 2002-08-05 | 2004-02-05 | Orchid Health Care | Novel pharmaceutical composition of ceftiofur |
KR20040015622A (ko) * | 2002-08-13 | 2004-02-19 | 대한뉴팜(주) | 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물 |
CN100534433C (zh) * | 2005-12-12 | 2009-09-02 | 浙江升华拜克生物股份有限公司 | 一种含头孢噻呋的兽用粉针注射剂 |
-
2009
- 2009-11-18 KR KR1020117014061A patent/KR101748890B1/ko active IP Right Grant
- 2009-11-18 JP JP2011537581A patent/JP5685193B2/ja active Active
- 2009-11-18 US US12/621,208 patent/US20100125060A1/en not_active Abandoned
- 2009-11-18 CN CN200980152552.1A patent/CN102341125B/zh active Active
- 2009-11-18 BR BRPI0922041A patent/BRPI0922041A8/pt not_active Application Discontinuation
- 2009-11-18 CA CA2743551A patent/CA2743551C/en active Active
- 2009-11-18 ES ES09764376.1T patent/ES2693700T3/es active Active
- 2009-11-18 NZ NZ592984A patent/NZ592984A/xx unknown
- 2009-11-18 EP EP09764376.1A patent/EP2367572B1/en active Active
- 2009-11-18 WO PCT/US2009/064978 patent/WO2010059717A2/en active Application Filing
- 2009-11-18 MX MX2011005217A patent/MX2011005217A/es active IP Right Grant
- 2009-11-18 AU AU2009316708A patent/AU2009316708B2/en active Active
-
2011
- 2011-05-12 ZA ZA2011/03479A patent/ZA201103479B/en unknown
- 2011-05-19 CL CL2011001177A patent/CL2011001177A1/es unknown
- 2011-06-07 CO CO11069892A patent/CO6390043A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2012509337A (ja) | 2012-04-19 |
WO2010059717A2 (en) | 2010-05-27 |
AU2009316708A1 (en) | 2010-05-27 |
ZA201103479B (en) | 2012-02-29 |
CN102341125A (zh) | 2012-02-01 |
JP5685193B2 (ja) | 2015-03-18 |
BRPI0922041A2 (pt) | 2015-12-22 |
EP2367572B1 (en) | 2018-08-29 |
CN102341125B (zh) | 2014-02-12 |
KR101748890B1 (ko) | 2017-06-19 |
KR20110092312A (ko) | 2011-08-17 |
NZ592984A (en) | 2012-12-21 |
WO2010059717A3 (en) | 2011-09-09 |
US20100125060A1 (en) | 2010-05-20 |
CL2011001177A1 (es) | 2011-09-16 |
EP2367572A2 (en) | 2011-09-28 |
ES2693700T3 (es) | 2018-12-13 |
AU2009316708B2 (en) | 2014-07-17 |
CA2743551A1 (en) | 2010-05-27 |
MX2011005217A (es) | 2011-06-01 |
BRPI0922041A8 (pt) | 2022-08-16 |
CA2743551C (en) | 2017-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6390043A2 (es) | Formulaciones que comprenden ceftiofur y cetoprofeno o ceftiofur y alcohol bencílico | |
ES2524320T3 (es) | Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo | |
CL2018001762A1 (es) | Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas. (divisional solicitud 201402087). | |
CY1120888T1 (el) | Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες | |
ES2564172T3 (es) | Utilización de una composición cosmética para el cuidado de las pieles grasas | |
AR078846A1 (es) | Composicion para el tratamiento de la enfermedad de alzheimer | |
GT200600350A (es) | Formulaciones líquidas | |
AR055123A1 (es) | Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta, composicion farmaceutica que la contiene y su aplicacin en terapeutica | |
CL2008003096A1 (es) | Compuestos derivados de piperidino-dihidrotienopirimidinas; inhibidores pde4; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos o enfermedades de las vias respiratorias o gastrointestinales, como tambien enfermedades inflamatorias de las articulaciones u ojos, entre otras. | |
CL2008001297A1 (es) | N-[(1s)-1-(5-fluoropirim idin-2-i1 )etil]-3-(5-isopropoxi-1 h-pirazol-3-il )-3h-imidazo[4,5-b]piridin-5amina o una sal farmacéuticamente aceptabie del mismo; composición farmacéutica que lo comprende; y su uso en el tratamiento del cáncer. | |
BR112012022797A2 (pt) | composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool | |
GT201000160A (es) | Derivados de aminobenzamida como agentes útiles para el control de parásitos de animales | |
CL2009000600A1 (es) | Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas. | |
BR122019021238B8 (pt) | uso de um inibidor do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd) | |
ECSP056074A (es) | Composiciones y método para tratar las infecciones microbianas y parasitarias en el ganado y otros animales | |
EP4403197A3 (en) | Injectable formulations for organ augmentation | |
AR048718A1 (es) | Uso de formulaciones de meloxicam en medicina veterinaria | |
AR080721A1 (es) | 1-((3-ciano-piridin-2-il) metil]-3-metil-7-(2-butin-1-il)-8- (3-(r)- amino-piperidin-1-il)- xantina para tratamiento de un trastorno metabolico de un animal no humano predominantemente carnivoro | |
SI2219665T1 (sl) | Formulacije paratiroidnega hormona in njihove uporabe | |
CL2008002984A1 (es) | Composicion farmaceutica que comprende micofenolato sodico y su uso para el tratamiento y/o prevencion en enfermedades autoinmunes tales como el rechazo de aloinjertos o xenoinjertos de organos, celulas o tejidos y como antiinflamatorio. | |
CL2007002818A1 (es) | Procedimiento para combatir plagas animales u hongos fitopatogenos; composicion agroquimica para la aplicacion en el suelo que contiene al menos un principio activo agroquimico y un adyuvante; uso del adyuvante para preparar composiciones agroquimica | |
PE20120797A1 (es) | Derivados de 1-[(3'-fluoro-4'-hidroximetil-5'-metilsulfonil)bifenil-4-il]-2-bencil-4-[(1-hidroxi-1-metil)etil]-1h-imidazol como moduladores de lxr | |
AR082030A1 (es) | Composiciones farmaceuticas topicas que comprenden flurbiprofeno, uso y metodo de tratamiento | |
BR112016003381A8 (pt) | sistema para administrar uma formulação de cantaridina a um indivíduo; dispositivo aplicador para administrar uma formulação de cantaridina a um indivíduo; usos de uma formulação de cantaridina; kit para administrar uma formulação de cantaridina a um indivíduo; formulações; e formulação de cantaridina | |
CL2009000246A1 (es) | Compuestos derivados de 1h-imidazo[4,5-b]piridin-2-ol; moduladores de la contraccion sarcomero; composicion farmaceutica que comprende; kit farmaceutico; y uso en el tratamiento de enfermedades neuromusculares, tales como atrofia, fatiga, claudicacion, en entre otras. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |